Immunovant, Inc. (IMVT) stock
IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
$33.21−0.07 (-0.21%)
Close on Nov 17, 2026Market cap $6.86BP/E –Yield –
Immunovant total assets
Total assets on the balance sheet at the end of each period.
Immunovant's total assets was $852.49M at Jun 30, 2026. For fiscal 2026 it was $957.01M, up 23.3% from the year before. The highest annual figure on record is $957.01M in fiscal 2026.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $957.01M | +23.3% |
| FY2025 | Mar 31, 2025 | $776.22M | +16.5% |
| FY2024 | Mar 31, 2024 | $666.37M | +64.2% |
| FY2023 | Mar 31, 2023 | $405.84M | -21.3% |
| FY2022 | Mar 31, 2022 | $515.56M | +25.0% |
| FY2021 | Mar 31, 2021 | $412.49M | +277.1% |
| FY2020 | Mar 31, 2020 | $109.39M | +691.1% |
| FY2019 | Mar 31, 2019 | $13.83M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $852.49M | +28.9% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $957.01M | +23.3% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $1.05B | +150.0% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $582.96M | +13.0% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $661.44M | +12.2% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $776.22M | +16.5% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $420.93M | -40.8% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $515.71M | +76.6% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $589.68M | +67.9% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $666.37M | +64.2% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $711.45M | +55.9% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $292.07M | -31.8% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $351.22M | -23.4% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $405.84M | -21.3% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $456.24M | -16.0% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $428.15M | -24.5% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $458.66M | +18.2% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $515.56M | +25.0% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $543.18M | +25.4% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $566.73M | +24.9% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $388.03M | +33.7% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $412.49M | +277.1% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $433.03M | +267.6% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $453.90M | +286.6% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $290.29M | +1999.3% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $109.39M | +26909.1% |
| Q3 FY2020CQ4 2018 | Sep 30, 2019 | $117.79M | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $117.42M | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $13.83M | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $405.00K | – |
See a number that looks wrong?